Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
95,963,102
-
Total 13F shares
-
88,841,761
-
Share change
-
+1,139,858
-
Total reported value
-
$3,218,912,230
-
Put/Call ratio
-
97%
-
Price per share
-
$36.21
-
Number of holders
-
296
-
Value change
-
+$30,616,545
-
Number of buys
-
155
-
Number of sells
-
147
Institutional Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q1 2025
As of 31 Mar 2025,
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) was held by
296 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
88,841,761 shares.
The largest 10 holders included
VANGUARD GROUP INC, BlackRock, Inc., SANDS CAPITAL MANAGEMENT, LLC, PRICE T ROWE ASSOCIATES INC /MD/, STATE STREET CORP, WELLINGTON MANAGEMENT GROUP LLP, Clearbridge Investments, LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., FEDERATED HERMES, INC., and SUVRETTA CAPITAL MANAGEMENT, LLC.
This page lists
297
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.